SRPT INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Announces Investigation into Sarepta Therapeutics, Inc. and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the FirmBusiness Wire • 03/23/23
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Sarepta Therapeutics, Inc. (SRPT) InvestigationBusiness Wire • 03/21/23
Sarepta Therapeutics (SRPT) Soars 7.1%: Is Further Upside Left in the Stock?Zacks Investment Research • 03/21/23
INVESTOR NOTICE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - SRPTPRNewsWire • 03/20/23
EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – SRPTBusiness Wire • 03/17/23
Sarepta Therapeutics plummets 20% after FDA contradicts company and requires advisory meetingMarket Watch • 03/16/23
Sarepta Therapeutics Announces Advisory Committee Meeting will be Held for SRP-9001Business Wire • 03/16/23
Sarepta's stock still up after Tuesday's announcement that its Duchenne drug candidate won't require a FDA AdCom meetingMarket Watch • 03/01/23
Sarepta Therapeutics pops as results top estimates and Morgan Stanley raises share price to $187Proactive Investors • 03/01/23
Sarepta Rockets And Breaks Out As FDA Smooths The Path For Its Gene TherapyInvestors Business Daily • 03/01/23